Opening question: When a peptide ad cites a “new study” with a bioRxiv or medRxiv link, how do you tell a preprint from a peer-reviewed paper—without treating the PDF as settled clinical proof?
Short answer: read the server’s own rules. bioRxiv and medRxiv distribute unpublished manuscripts before journal certification. Appearance on either server is not peer review, journal acceptance, or an endorsement of methods or conclusions.
A practical preprint-vs-paper checklist when ads say “new studies show…”:
- Look for the preprint label: bioRxiv states articles are not peer-reviewed, edited, or typeset before posting; they receive basic screening (including for non-scientific content and certain risk categories), and posting does not imply endorsement of scientific quality. medRxiv’s FAQ similarly stresses that preprints are unrefereed and may contain errors.
- Separate screening from peer review: Screening checks for plagiarism, inappropriate types, and certain public-health risk patterns. It is not the same as journal peer review, where editors use expert referees before formal publication.
- Check whether a journal version exists: bioRxiv notes it usually links a published version after journal publication when a match is found. If the ad only shows a preprint DOI, ask whether a peer-reviewed citation exists—and read that version’s abstract and limitations, not only the social headline.
- Species and intent still matter: A life-science or health-science preprint can be animal-only, in vitro, or early human observational work. A catalog screenshot next to a preprint DOI does not convert research-use merchandise into an approved therapy.
Preprint literacy is evidence hygiene. It is not a shopping guide. Company research-only catalogs document laboratory intent and paperwork such as certificates of analysis; they do not upgrade a preprint into a label claim. For company facts only—not clinical evidence—Apollo Peptides states products are for laboratory research only, not for human or veterinary use, and describes third-party testing with certificates of analysis.
Bottom line: Open the bioRxiv/medRxiv about pages, treat preprints as uncertified manuscripts, and look for a journal version before repeating “new study” claims from peptide ads. That habit changes what you forward—it is not advice to buy, inject, or dose any peptide.
By The Everyday Brief · AI-assisted editorial. Drafted with AI research assistance; claims checked against bioRxiv About and medRxiv FAQ pages opened on 2026-09-22 PT. No invented studies, quotes, or dosing. Not medical or legal advice.
Sources
1. bioRxiv — About bioRxiv (preprints; not peer-reviewed)
2. medRxiv — FAQ (unrefereed preprints; screening vs peer review)
3. Apollo Peptides (company facts only)
Related reading
How to use PubMed and PMC to check whether a peptide “study” ad is animal-only or human
A MedlinePlus checklist for peptide “study” headlines before you forward them
A peptide headline is not a result: reading studies without the hype